NasdaqGM - Delayed Quote • USD
Adicet Bio, Inc. (ACET)
At close: April 24 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 8 | 7 |
| Avg. Estimate | -0.39 | -0.35 | -1.86 | -1.88 |
| Low Estimate | -0.51 | -0.39 | -3.05 | -3.41 |
| High Estimate | -0.27 | -0.27 | -1.09 | -1.05 |
| Year Ago EPS | -0.72 | -0.75 | -3.31 | -1.86 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 8 | 6 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | 12.67M | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.69 | -0.68 | -0.74 | -0.69 |
| EPS Actual | -0.72 | -0.75 | -1.16 | -0.69 |
| Difference | -0.03 | -0.07 | -0.42 | 0 |
| Surprise % | -4.30% | -10.30% | -56.80% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.39 | -0.35 | -1.86 | -1.88 |
| 7 Days Ago | -0.39 | -0.35 | -1.86 | -1.88 |
| 30 Days Ago | -0.39 | -0.35 | -1.78 | -1.77 |
| 60 Days Ago | -0.58 | -0.56 | -2.44 | -2.05 |
| 90 Days Ago | -0.75 | -0.77 | -2.64 | -2.13 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ACET | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 45.80% | -- | -- | 1.50% |
| Next Qtr. | 53.30% | -- | -- | 11.40% |
| Current Year | 43.80% | -- | -- | 5.20% |
| Next Year | -1.10% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 29.10% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Wedbush: Outperform to Outperform | 4/23/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/2/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/20/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 3/20/2024 |
| Reiterates | Canaccord Genuity: Buy to Buy | 3/20/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/2/2024 |
Related Tickers
TARA Protara Therapeutics, Inc.
2.8200
-6.00%
SILO Silo Pharma, Inc.
1.8800
+5.62%
TOVX Theriva Biologics, Inc.
0.3686
-2.20%
NKTX Nkarta, Inc.
7.17
-5.16%
KPTI Karyopharm Therapeutics Inc.
1.0900
0.00%
STOK Stoke Therapeutics, Inc.
11.66
+3.64%
IMUX Immunic, Inc.
1.2400
0.00%
AFMD Affimed N.V.
4.8800
-8.79%
ALGS Aligos Therapeutics, Inc.
0.8290
+0.66%
BNTC Benitec Biopharma Inc.
6.72
-2.04%